Andy Studna is a Senior Editor at Pharmaceutical Commerce Magazine. He specializes in areas related to medicine and healthcare, including healthcare technology, diagnostics, and supply chain management. Andy's insights and expertise are featured in notable publications such as Pharmaceutical Executive, Applied Clinical Trials Magazine, and Medical Device & Technology.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Andy Studna’s articles predominantly focus on healthcare and pharmaceuticals, often citing data and featuring expert commentary. He seems to have a keen interest in emerging trends, technological advancements, and regulatory changes within the healthcare industry.
Given his coverage attributes show a high percentage of citing data, he likely values pitches supported by robust statistics and studies relevant to the topics he covers.
Considering his broad range of topics covered within healthcare & pharmaceutical themes, experts from various disciplines such as medical professionals, researchers or policy makers could provide valuable insights for Andy's articles.
As no specific geographic focus is mentioned for Andy Studna, it can be assumed that international perspectives on global health matters would also be welcomed.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Gaynor Anders, Andy Studna
In this video interview, Gaynor Anders, chief delivery officer at Trialbee, outlines the organizational, budgetary, and technological changes sponsors need to make to move from study-by-study recruitment to a portfolio-level approach that keeps patients engaged across a therapeutic area.
By: Rob Dicicco, Andy Studna
In this Q&A, Rob DiCicco, vice president of portfolio management at TransCelerate Biopharma, discusses the collaborative work underway with FDA and CTTI to explore selective safety data collection as a model for de-risking trial design, reducing site and patient burden, and scaling pragmatic trial approaches across the industry.
By: Andy Studna
New peer-reviewed research combining real-world RBQM data with Tufts CSDD benchmarks finds ROI multiples as high as 23x, with time savings identified as the primary driver of financial value.
By: Elizabeth Walsh, Andy Studna
In this video interview, Elizabeth Walsh, founder of Walsh Clinical Advisory and co-author of The Clinical Execution Blueprint, makes the case that the assumptions accumulated at the moment of a product development decision govern everything that follows—and why deferring that work doesn't save time, it just makes it more expensive to fix.
By: Andy Studna
Bayer and Henry Ford Health announce a strategic research alliance, while Massive Bio and FOMAT launch an AI-driven oncology prescreening pilot—both targeting barriers that keep eligible patients from reaching clinical trials.
By: Raviv Pryluk, Andy Studna
In this video interview, Raviv Pryluk, CEO and co-founder of PhaseV, explains why the gap between data collection and analysis-ready data undermines the promise of continuous trial monitoring and what it will take to close it.
By: Raviv Pryluk, Andy Studna
In this video interview, Raviv Pryluk, CEO and co-founder of PhaseV, breaks down the standardization and mapping work that must happen before streaming data can be analyzed meaningfully—and how AI is beginning to make that process fast enough to enable real-time monitoring at scale.
By: Raviv Pryluk, Andy Studna
In this video interview, Raviv Pryluk, CEO and co-founder of PhaseV, makes the case that scaling real-time data review requires an ecosystem approach—bringing regulators, sponsors, CROs, and technology vendors together in a shared learning environment rather than letting progress remain siloed.
By: Andy Studna
As agentic AI, automated data harmonization, and real-time monitoring reshape clinical development, the organizations seeing meaningful results are those that have invested in unified data infrastructure and disciplined governance rather than cycling through pilots without the foundation to scale them.
By: Raviv Pryluk, Andy Studna
In this video interview, Raviv Pryluk, CEO and co-founder of PhaseV, outlines a gradual, win-driven strategy for making real-time monitoring stick—starting in early phases and building toward pivotal trials with the right technology partners and a network effect that scales.
